Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

Katharina Holstein, MD, Andrea Smith, Paul Knöbl, MD PhD, Christiane Dobbelstein, MD, Wolfgang A. Miesbach, MD PhD, Michael Spannagl, MD PhD, Jürgen Heinz, MD PhD, Ute Scholz, MD, Hermann Eichler, MD, Angela Huth-Kühne, MD, Robert Klamroth, MD PhD, Armin Koch, MD PhD, Andreas Tiede, MD

Blood (2017) 130 (Supplement 1): 22.

https://doi.org/10.1182/blood.V130.Suppl_1.22.22

Published: 2017

Journal Articles

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Andreas Tiede, Christoph J. Hofbauer, Sonja Werwitzke, Paul Knöbl, Saskia Gottstein, Rüdiger E. Scharf, Jürgen Heinz, Jürgen Groß, Katharina Holstein, Christiane Dobbelstein, Fritz Scheiflinger, Armin Koch, Birgit M. Reipert

Blood (2016) 127 (19): 2289–2297.

https://doi.org/10.1182/blood-2015-09-672774

Published: 2016

Includes: Supplemental data

Journal Articles

Lower Relapse Incidence and Relapse Mortality in Patients Transplanted from a Younger Sibling in HLA-Identical Stem Cell Transplantation: Does Microchimerism Matter?

Christiane Dobbelstein, MD, Haytham Kamal, MD, Elke Dammann, Eva Mischak-Weissinger, MD, PhD, Michael Stadler, MD, PhD, Juergen Krauter, MD, PhD, Arnold Ganser, MD, PhD, Matthias Eder, MD, PhD

Blood (2008) 112 (11): 343.

https://doi.org/10.1182/blood.V112.11.343.343

Published: 2008

Journal Articles

Immunosuppression for Patients with Low and Intermediate Risk Myelodysplastic Syndrome: A Prospective Randomized Multicenter Trial Comparing Antithymocyte Globulin + Cyclosporine with Best Supportive Care: SAKK 33/99.

Jakob R. Passweg, Aristoteles Giagounidis, Mathew Simcock, Carlo Aul, Christiane Dobbelstein, Michael Stadler, Gert Ossenkoppele, Wolf K. Hofmann, Andre Tichelli, Arnold Ganser

Blood (2007) 110 (11): 1461.

https://doi.org/10.1182/blood.V110.11.1461.1461

Published: 2007

Journal Articles

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

Michael Lübbert, Björn Rüter, Mathias Schmid, Sabine Knipp, Ulrich Germing, Christiane Dobbelstein, Hartmut Eimermacher, Barbara Deschler, Rainer Claus, Richard Schlenk, Arnold Ganser, Hartmut Döhner, Claudia Schmoor, Hartmut Henß

Blood (2005) 106 (11): 1852.

https://doi.org/10.1182/blood.V106.11.1852.1852

Published: 2005

NARROW

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Lower Relapse Incidence and Relapse Mortality in Patients Transplanted from a Younger Sibling in HLA-Identical Stem Cell Transplantation: Does Microchimerism Matter?

Immunosuppression for Patients with Low and Intermediate Risk Myelodysplastic Syndrome: A Prospective Randomized Multicenter Trial Comparing Antithymocyte Globulin + Cyclosporine with Best Supportive Care: SAKK 33/99.

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Factor VIII Activity and Risk of Bleeding in Acquired Hemophilia a: Results from the Gth-AH 01/2010 Study

Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Lower Relapse Incidence and Relapse Mortality in Patients Transplanted from a Younger Sibling in HLA-Identical Stem Cell Transplantation: Does Microchimerism Matter?

Immunosuppression for Patients with Low and Intermediate Risk Myelodysplastic Syndrome: A Prospective Randomized Multicenter Trial Comparing Antithymocyte Globulin + Cyclosporine with Best Supportive Care: SAKK 33/99.

Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only